Clinical Trial: Triapine and Lutetium Lu 177 Dotatate for Neuroendocrine Tumors

Translate

What is PRRT?

I’m guessing most of my readers know what Peptide Receptor Radiotherapy (PRRT) is.  But for those new to this field, read more here

What is Triapine?

Triapine is a ribonucleotide reductase (RNR) inhibitor, I.e. it helps repair DNA.  When I research this drug, I can see it is used in numerous examples of clinical trials in an anti-cancer setting alongside radiotherapy and chemotherapy, in many cancers.

Triapine in NET

There is currently a trial of Triapine with Lutathera (PRRT) (11 major US hospitals).  This study was testing the hypothesis that triapine is an effective radiation sensitizer that can be safely combined with peptide receptor radionuclide therapy and can improve antitumor activity of Lutetium Lu 177 Dotatate, e.g. increase the objective response rate (ORR) above that found in standalone clinical trials, e.g. NETTER-1.   A trial sponsored by Markey Cancer Center has recently completed Phase 1 and has been granted permission to progress to a randomised phase 2 study, a clear indication the Phase 1 study was successful and warranted further progression.  

The Clinical Trial Document (phase 1) – NCT04234568

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors – Full Text View – ClinicalTrials.gov

It is not yet known whether the existing Phase 1 clinical trials doc above will be converted to Phase 2 or a new one will be entered into the database.  Nor is it yet known that the trial locations will be less, the same, or extended; I will keep you informed via this post.

Phase 1 trial data

To be confirmed. Watch this space.

Additional Information

This trial is also evaluating NETest, a novel blood-based test that evaluates levels of 51 neuroendocrine tumor gene transcripts. In addition, the study will correlate clinical outcome with baseline somatostatin receptor density, somatic tumor mutations and germline mutations.

Read more about NETest by clicking here

General Clinical Trials Disclaimer

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact. 

Inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan. 

 
 

Disclaimer

I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.  Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional as they are not members of the private group or followers of my sites in any official capacity.  Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.

Subscribe to my newsletter

Thanks for reading.

Ronny

I’m also active on Facebook. Like my page for even more news. Help me build up my new site here – click here and ‘Like’

Sign up for my newsletters – Click Here

Disclaimer

My Diagnosis and Treatment History

Follow me on twitter

Check out my online presentations

Check out my WEGO Health Awards

Remember ….. in the war on Neuroendocrine Cancer, let’s not forget to win the battle for better quality of life!

patients included

Please Share this post for Neuroendocrine Cancer awareness and to help another patient

 
 
 

New PET findings after COVID-19 vaccination: Keep Calm and Carry On?

After a few months of introducing C-19 vaccines, many cases of false-positive lymph nodes were reported on nuclear PET scans, some of which led to

Read More »

Clinical Trial: Triapine and Lutetium Lu 177 Dotatate for Neuroendocrine Tumors

What is PRRT? I’m guessing most of my readers know what Peptide Receptor Radiotherapy (PRRT) is.  But for those new to this field, read more

Read More »

CAPTEM for Neuroendocrine Tumours

What is CAPTEM?  Capecitabine is an oral drug used alone or with other drugs to treat certain types of colorectal cancer and breast cancer. It

Read More »

Living with Cancer: Don’t cross the bridge until you come to it

When I read comments in my private Facebook community group, I can see that many people do get concerned about upcoming scans and other rest

Read More »

Clinical Trial: Dostarlimab, anti–PD-1 monoclonal antibody in Neuroendocrine Carcinoma

Whenever I post about a new trial or study, some people get excited without understanding that these new treatments and capabilities can very often take

Read More »

Low and High Residue Foods

It’s clear that no single diet is suitable for everyone, there are just too many variables in Neuroendocrine Cancer. They are a heterogeneous grouping of

Read More »

I love comments - feel free!

%d bloggers like this: